Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2013 by University of Minnesota - Clinical and Translational Science Institute
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute Identifier:
First received: April 26, 2012
Last updated: March 29, 2013
Last verified: March 2013

Fabry disease is an X-linked lysosomal storage disorder which results from reduced activity of the enzyme α-galactosidase A. Accumulation of globotriaosylceramide (GL-3) causes disturbances in multiple organ systems. Patients often complain of acroparesthesia, caused by small fiber neuropathy. Limited information is available regarding effective treatments for small fiber neuropathic pain in Fabry disease and no standard of care exists. Opioid analgesics are often used because of their pharmacokinetic properties. The use of opioids, while effective, has complications such as constipation, physical dependence, and addiction. The purpose of this study is to determine efficacy of gabapentin vs. placebo at controlling peripheral neuropathic pain and reducing the use of opioid analgesics. The investigators are conducting a randomized, double-blind, placebo controlled, single center, cross-over study. The primary endpoint is percent reduction in hydrocodone-acetaminophen use.

Condition Intervention Phase
Fabry Disease
Neuropathic Pain
Drug: Gabapentin
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Placebo Controlled Trial Evaluating Gabapentin for the Treatment of Small Fiber Neuropathic Pain in Patients With Fabry Disease

Resource links provided by NLM:

Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • average reduction in hydrocodone-acetaminophen use [ Time Frame: assessed at the end of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number and type of adverse events [ Time Frame: assessed at the end of the study ] [ Designated as safety issue: Yes ]
  • Pain levels [ Time Frame: assessed at the end of the study ] [ Designated as safety issue: No ]
  • Define therapeutic level for gabapentin [ Time Frame: assessed at the end of the study ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: April 2012
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: gabapentin Drug: Gabapentin
gabapentin 100 mg capsules
Placebo Comparator: placebo Drug: placebo
compounded placebo capsules


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of Fabry Disease
  • age ≥ 18 years of age at study enrollment
  • current neuropathic pain at any severity level

Exclusion Criteria:

  • known sensitivity or allergy to study drug
  • history of illicit drug use
  • pregnancy
  • suicidal thoughts at study enrollment as assess by the C-SSRS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01588314

Contact: Jeanine Utz, PharmD 612-626-5131
Contact: Colleen Doyen, BA 612-672-5213

United States, Minnesota
University of Minnesota, Fariview Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Jeanine Utz, PharmD    612-626-5131   
Sub-Investigator: Chester Whitley, PhD, MD         
Principal Investigator: Jeanine Utz, PharmD         
Sub-Investigator: Kyle Rudser, PhD         
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Genzyme, a Sanofi Company
Principal Investigator: Jeanine Utz, PharmD University of Minnesota, Fairview
  More Information

No publications provided

Responsible Party: University of Minnesota - Clinical and Translational Science Institute Identifier: NCT01588314     History of Changes
Other Study ID Numbers: 1112M07943
Study First Received: April 26, 2012
Last Updated: March 29, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
Fabry disease
neuropathic pain

Additional relevant MeSH terms:
Fabry Disease
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Cardiovascular Diseases
Central Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Diseases
Peripheral Nervous System Diseases
Signs and Symptoms
Vascular Diseases
Anti-Anxiety Agents
Anti-Dyskinesia Agents processed this record on November 25, 2014